# Evaluate Immune Response Approximately 5 to 6 Years After Receiving Different Formulations of GSK Bio Hep B Vaccine

> **NCT00329576** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 632 (—)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** Hepatitis B vaccine

## Key facts

- **NCT ID:** NCT00329576
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** —
- **Final completion:** 2006-08
- **Target enrollment:** 632 (—)
- **Last updated:** 2016-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00329576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00329576, "Evaluate Immune Response Approximately 5 to 6 Years After Receiving Different Formulations of GSK Bio Hep B Vaccine". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00329576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*